New test may expand who benefits from ovarian cancer drug
Knowledge-focused
Terminated
This study tested a new lab method (RAD51 assay) to see if it could better predict which patients with recurrent ovarian cancer would respond to the drug olaparib. The goal was to find more patients who could benefit, beyond those with BRCA gene mutations. The study was stopped e…
Phase: PHASE2 • Sponsor: Leiden University Medical Center • Aim: Knowledge-focused
Last updated Jun 16, 2026 23:20 UTC